Wall Street analyst estimates for Septerna Inc (SEPN): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Consensus price target
$50.40 (+5% vs price $47.88)
between $43.00 and $60.00 · 4 targets published in the last quarter
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $96.0M | $59.0M – $118M | -$1.35 | 7 |
| 2027E | $73.6M | $59.5M – $89.9M | -$2.28 | 7 |
| 2028E | $67.0M | $42.2M – $82.2M | -$2.70 | 8 |
Figures in USD · consensus as of November 4, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 8 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (−2 sell to +2 buy) | 1.11 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.41 | ||
| 2026-08-10 | $-0.29 | $-0.43 | +31.9% |
| 2026-05-12 | $-0.19 | $-0.51 | +62.7% |
| 2026-03-09 | $-0.24 | $-0.23 | -4.3% |
| 2025-11-10 | $-0.09 | $0.19 | -147.4% |
| 2025-08-11 | $-0.56 | $-0.05 | -1020.0% |
| 2025-05-15 | $-0.49 | $-0.38 | -28.9% |
| 2025-03-27 | $-0.64 | $-0.69 | +7.2% |
Valuation Ratios
| Price / Book | 5.58 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $151,000 | $1.1M | $46.0M |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | $151,000 | $1.1M | $46.0M |
| Research & Development | $36.0M | $65.3M | $97.6M |
| Selling, General & Admin | $9.7M | $16.6M | $29.2M |
| Operating Expenses | -$1.9M | $81.9M | $126.7M |
| Operating Income | $2.1M | -$80.8M | -$80.8M |
| EBITDA | -$44.7M | -$70.9M | -$47.3M |
| Interest Expense | 0 | 0 | 0 |
| Pre-tax Income | $4.9M | -$72.3M | -$48.9M |
| Income Tax | $691,000 | -$498,000 | $12,000 |
| Net Income | $4.2M | -$71.8M | -$48.9M |
| EPS | $0.03 | -$1.93 | -$1.10 |
| EPS (Diluted) | $0.03 | -$1.93 | -$1.10 |
| Shares Outstanding (Diluted) | 19.5 M | 37.2 M | 44.3 M |
Price
| Price | $47.88 (closing price, November 4, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: MBX · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks